Antisense Therapeutics Ltd Phase II Trial Final Data Results Webinar Transcript
Welcome, everyone. Good morning, good afternoon, or good evening from wherever you have called in. We're really pleased that you're here. My name is Pat Furlong and I'm from PPMD, and we're welcoming today, the Antisense Therapeutics group. Mark Diamond is here as well as his colleague, Nuket Desem.
They have considerable experience in drug development. And I think for our community, this might be a little confusing with Antisense Therapeutics and our Antisense oligonucleotides that are exon-skipping drugs. These -- the drug ATL1102, that they're going to present to you has a different mode of action. So I hope you listen, this is a great opportunity, and this particular approach would apply to every young man with Duchenne muscular dystrophy.
So with that, I'll turn it over to Mark Diamond to begin. Mark?
Thank you. Thank you, Pat, and the team at PPMD for the opportunity to speak today on Antisense Therapeutics Duchenne
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |